Daniel James George, MD

Professor of Medicine

Professor in Surgery

Member of the Duke Cancer Institute

Campus mail Duke Box 103861, Durham, NC 27710

Phone (919) 668-4615

Email address daniel.george@duke.edu

Education and Training

Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
M.D., Duke University, 1992

Grants

An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients with Prostate Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Disparities in the Use of Oral Anticancer Agents in Kidney Cancer
ODYSSEY RCC
Reducing prostate cancer aggressiveness via aptamer-mediated nuclear delivery of splice-switching oligonucleotides
Race-related germline genetic variation and response to secondary hormonal therapy in metastatic castration-resistant prostate cancer
Race-Related Alternative Splicing: Novel Targets in Prostate Cancer
A Phase II open-label, Multicenter study of Apalutamide, Abiraterone Acetate and Prednisone in African American and Caucasian men with metastatic castrate-resistant prostate cancer
A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-resistant Prostate Cancer and DNA-Repair Anomalies
Therapeutic targeting of cystine addiction of renal cell carcinoma
PCRP Clinical Consortium: Duke University Clinical Research Site
Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer
Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer
ABI-RACE: A Phase II Open Label, Parallel group study of Abiraterone Acetate in African American and Caucasian Men with Metastic Castrate Resistant Prostate Cancer
Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer
Advancing Cancer Care in the Rural Southeast: Delivering Novel Therapies In Our Community Cancer Centers
Targeting RNA splicing in race-related aggressive and lethal prostate cancer
Validation and interrogation of differentially expressed and alternatively spliced genes in African American prostate cancer

Publications

Shah, Anand, Thomas J. Polascik, Daniel J. George, John Anderson, Terry Hyslop, Alicia M. Ellis, Andrew J. Armstrong, et al. “Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.” In J Gen Intern Med, 2020. https://doi.org/10.1007/s11606-020-06124-2.

PMID

32875501

Full Text

Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (August 15, 2020): 112250. https://doi.org/10.1016/j.bios.2020.112250.

PMID

32392161

Full Text

Zhang, Tian, Michael R. Harrison, Peter H. O’Donnell, Ajjai S. Alva, Noah M. Hahn, Leonard J. Appleman, Jeremy Cetnar, et al. “A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.” Cancer, August 5, 2020. https://doi.org/10.1002/cncr.33067.

PMID

32757302

Full Text

Bitting, Rhonda L., Michael Goodman, and Daniel J. George. “Racial Disparity in Response to Prostate Cancer Systemic Therapies.” Curr Oncol Rep 22, no. 9 (July 23, 2020): 96. https://doi.org/10.1007/s11912-020-00966-z.

PMID

32700096

Full Text

Rencsok, Emily M., Latifa A. Bazzi, Rana R. McKay, Franklin W. Huang, Adam Friedant, Jake Vinson, Samuel Peisch, et al. “Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions.” Cancer Epidemiol Biomarkers Prev 29, no. 7 (July 2020): 1374–80. https://doi.org/10.1158/1055-9965.EPI-19-1616.

PMID

32503813

Full Text

Shore, Neal D., Fred Saad, Michael S. Cookson, Daniel J. George, Daniel R. Saltzstein, Ronald Tutrone, Hideyuki Akaza, et al. “Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.” N Engl J Med 382, no. 23 (June 4, 2020): 2187–96. https://doi.org/10.1056/NEJMoa2004325.

PMID

32469183

Full Text

Bakthavatsalam, Subha, Petpailin Wiangnak, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.” Bioorg Med Chem Lett 30, no. 11 (June 1, 2020): 127148. https://doi.org/10.1016/j.bmcl.2020.127148.

PMID

32253061

Full Text

Shore, Neal, Celestia S. Higano, Daniel J. George, Cora N. Sternberg, Fred Saad, Bertrand Tombal, Kurt Miller, et al. “Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis, May 13, 2020. https://doi.org/10.1038/s41391-020-0236-0.

PMID

32404868

Full Text

Ramaswamy, Krishnan, Stanislav Lechpammer, Jack Mardekian, Ahong Huang, Neil M. Schultz, Rickard Sandin, Li Wang, Onur Baser, and Daniel J. George. “Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.” Adv Ther 37, no. 5 (May 2020): 2083–97. https://doi.org/10.1007/s12325-020-01260-x.

PMID

32112280

Full Text

Markham, Merry Jennifer, Kerri Wachter, Neeraj Agarwal, Monica M. Bertagnolli, Susan Marina Chang, William Dale, Catherine S. M. Diefenbach, et al. “Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.” J Clin Oncol 38, no. 10 (April 1, 2020): 1081. https://doi.org/10.1200/JCO.19.03141.

PMID

32013670

Full Text

Daniel James George, MD

Education and Training

Grants

Publications

Pages